| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.88▼ | 3.93▼ | 3.93▼ | 3.96▼ | 4.00▼ |
| MA10 | 3.90▼ | 3.95▼ | 3.92▼ | 4.04▼ | 4.14▼ |
| MA20 | 3.93▼ | 3.92▼ | 3.92▼ | 4.03▼ | 4.25▼ |
| MA50 | 3.96▼ | 3.98▼ | 4.07▼ | 4.20▼ | 3.54▲ |
| MA100 | 3.92▼ | 4.08▼ | 4.04▼ | 4.24▼ | 3.11▲ |
| MA200 | 4.04▼ | 4.07▼ | 4.12▼ | 3.75▲ | 3.51▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.007▼ | 0.001▲ | 0.008▲ | -0.006▼ | -0.094▼ |
| RSI | 33.951▼ | 40.906▼ | 41.178▼ | 42.080▼ | 48.433▼ |
| STOCH | 13.889▼ | 30.273 | 57.750 | 28.693 | 24.356 |
| WILL %R | -83.333▼ | -75.676▼ | -57.143 | -74.939 | -89.246▼ |
| CCI | -88.050 | -137.385▼ | -45.349 | -80.150 | -93.436 |
|
Thursday, September 10, 2020 05:06 AM
Anavex Life Sciences (NASDAQ:AVXL) has completed a Phase 2 clinical trial evaluating Anavex 2-73 (blarcamesine) in patients with Rett syndrome, a rare inherited neurological disorder that occurs ...
|
|
Thursday, September 10, 2020 04:28 AM
10, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...
|
|
Thursday, September 10, 2020 04:26 AM
Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 25/09/20 | 3.82 | 4.024 | 3.82 | 3.87 | 779,500 |
| 24/09/20 | 3.87 | 3.99 | 3.75 | 3.87 | 454,600 |
| 23/09/20 | 4.05 | 4.07 | 3.875 | 3.90 | 578,100 |
| 22/09/20 | 4.07 | 4.12 | 3.97 | 4.06 | 610,900 |
| 21/09/20 | 4.23 | 4.28 | 4.06 | 4.09 | 554,810 |
| 18/09/20 | 4.19 | 4.515 | 4.18 | 4.25 | 1,405,806 |
| 17/09/20 | 4.09 | 4.27 | 4.02 | 4.19 | 493,500 |
| 16/09/20 | 4.06 | 4.14 | 4.00 | 4.06 | 369,600 |
| 15/09/20 | 4.09 | 4.18 | 3.99 | 4.02 | 449,800 |
| 14/09/20 | 3.98 | 4.12 | 3.945 | 4.06 | 604,900 |
|
|
||||
|
|
||||
|
|